Acta anaesthesiologica Scandinavica · 1997
Granisetron reduces incidence of nausea and vomiting after breast surgery.
Источник пометил эту публикацию как отозванную.
Клиническое исследованиеСтатьяРандомизированное исследованиеОтозванная публикацияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujii Y, Tanaka H, Toyooka H
Аннотация
BACKGROUND: Postoperative nausea and vomiting (PONV) remains a troublesome problem. The study was performed to evaluate the antiemetic efficacy of prophylactic granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, on the incidence of PONV in patients undergoing general anaesthesia for breast surgery.
METHODS: In a randomized, placebo-controlled, double-blind study, 50 female patients, 45-68 years, were given a single dose of either placebo (saline, n = 25) or granisetron (40 micrograms.kg-1, n = 25) intravenously over 2-5 min immediately before the induction of anaesthesia. Postoperatively, during the first 24 hours after anaesthesia, the incidence of PONV and adverse events was recorded.
RESULTS: The treatment groups were similar for patient demographics, types of surgery, anaesthetic and postoperative management. Postoperatively, the incidence of PONV was 48% and 16% after administration of placebo and granisetron, respectively (P < 0.05). No differences in the incidence of other adverse events were observed between the two groups.
CONCLUSION: Granisetron is an effective antiemetic for preventing PONV in patients undergoing general anaesthesia for breast surgery.
METHODS: In a randomized, placebo-controlled, double-blind study, 50 female patients, 45-68 years, were given a single dose of either placebo (saline, n = 25) or granisetron (40 micrograms.kg-1, n = 25) intravenously over 2-5 min immediately before the induction of anaesthesia. Postoperatively, during the first 24 hours after anaesthesia, the incidence of PONV and adverse events was recorded.
RESULTS: The treatment groups were similar for patient demographics, types of surgery, anaesthetic and postoperative management. Postoperatively, the incidence of PONV was 48% and 16% after administration of placebo and granisetron, respectively (P < 0.05). No differences in the incidence of other adverse events were observed between the two groups.
CONCLUSION: Granisetron is an effective antiemetic for preventing PONV in patients undergoing general anaesthesia for breast surgery.